IPO listing ceremony held at the Korea Exchange on the 18th- “Another leap forward as a global company.”

Initial public offering price of 65,000 KRW record breaking numbers, including a competition ratio of 1,275 to 1 for institutions, and subscription deposits of 63 trillion KRW.

SK bioscience CEO Ahn Jae-yong and other officials take a commemorative photo at the Korea Exchange in Yeouido on March 18.

On the 18th, SK bioscience announced that the completion of its listing on the securities market (KOSPI), having held a ceremony at the Korea Exchange in Yeouido, Seoul.

The ceremony’s attendees included key executives such as Jaeyong Ahn, CEO of SK bioscience, Chan-joong Park, CEO of SK discovery, Byung-doo Sohn, Korea Exchange Chairman, Il-moon Jung, CEO of Korea Investment & Securities, Ung-kee Cho, Executive Vice-Chairman, of Mirae Asset Daewoo and Byung-un Yoon, Managing Director of NH Investment & Securities.

Jaeyong Ahn delivered the ceremonial speech where he said, “The valuable advice received during our preparation for listing will be reflected in management to produce strong performance. SK bioscience will actively engage the market under the principles of transparency and trust, such as arranging and securing the time necessary to assess ongoing business affairs along with the market.”

“The listing has turned a new page in the history of SK bioscience,” Mr. Ahn declared, adding, “We invite you to join us in writing a new chapter of initiative and innovation.”

SK bioscience confirmed its IPO price of 65,000 KRW per share in a forecast of demand for domestic and foreign institutional investors. On March 4th and 5th, 1,464 institutions participated in the forecast for stock demand, recording a competition rate of 1,275.47 to 1, making it the largest in KOSPI history.

From March 9th to 10th, more than 63 trillion KRW were collected as deposits in subscriptions by general investors, setting the highest record in the domestic capital market’s history.

This listing will secure a sustainable source of capital for SK bioscience to grow into a global vaccine bio company founded on innovative technology.

Specifically, funds from the public offering will be used for △ expansion of research institutes and production facilities for additional CMO projects such as biomedical products, △development of new pipelines such as mRNA platforms and immune enhancers, △formation of partnerships with foreign governments and state-run organizations for technical cooperation, and △M&As with overseas companies to enter the global market.